Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors



Status:Recruiting
Healthy:No
Age Range:Any - 21
Updated:1/20/2019
Start Date:May 14, 2014
End Date:May 2027
Contact:Tabatha E. Doyle, RN
Email:tabatha.doyle@stjude.org
Phone:901-595-2544

Use our guide to learn which trials are right for you!

Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT

This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the
treatment of patients younger than 22 years of age. Patients with recurrent or refractory
AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT
will receive alisertib as part of age- and risk-adapted chemotherapy. Radiation therapy will
be given to children ≥12 months of age. Patients with AT/RT and concurrent extra-CNS MRT are
eligible.

Alisertib will be administered as a single agent on days 1-7 of each 21-day cycle in all
recurrent patients enrolled on Stratum A. For the patients on the newly diagnosed strata (B,
C or D), alisertib will be administered in sequence with chemotherapy and radiotherapy.

This study has 3 primary strata: (A) children with recurrent/progressive AT/RT or extra-CNS
MRT, (B) children < 36 months-old with newly diagnosed AT/RT, (C) children > 36 months old
with newly diagnosed AT/RT. Children with concurrent MRT will be treated according to age and
risk stratification schemes outlined for strata B and C and will have additional treatment
for local control. Children with synchronous AT/RT will be treated with age and CNS
risk-appropriate therapy, and also receive surgery and/or radiation therapy for local control
of the non-CNS tumor.

PRIMARY OBJECTIVES

- To estimate the sustained objective response rate and disease stabilization in pediatric
patients with recurrent or progressive AT/RT (atypical teratoid rhabdoid tumor in the
CNS) (Stratum A1) treated with alisertib and to determine if the response is sufficient
to merit continued investigation of alisertib in this population.

- To estimate the sustained objective response rate and disease stabilization in pediatric
patients with recurrent or progressive extra-CNS MRT (malignant rhabdoid tumor outside
the CNS) (Stratum A2) treated with alisertib and to determine if the response is
sufficient to merit continued investigation of alisertib in this population.

- To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are younger
than 36 months of age at diagnosis with no metastatic disease (Stratum B1) treated with
alisertib in sequence with induction and consolidation chemotherapy and radiation
therapy (depending on age) and to determine if the rates are sufficient to merit
continued investigation of alisertib in this population.

- To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are younger
than 36 months of age at diagnosis, with metastatic disease (Stratum B2) treated with
alisertib in sequence with induction and consolidation chemotherapy and to determine if
the rates are sufficient to merit continued investigation of alisertib in this
population.

- To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are 3 years
of age or greater at diagnosis with no metastatic disease and gross total resection or
near total resection (Stratum C1) treated with alisertib in sequence with radiation
therapy and consolidation chemotherapy and to determine if the rates are sufficient to
merit continued investigation of alisertib in this population.

- To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are 3 years
of age or greater at diagnosis with metastatic or residual disease (Stratum C2) treated
with alisertib in sequence with radiation therapy and consolidation chemotherapy and to
determine if the rates are sufficient to merit continued investigation of alisertib in
this population.

- To characterize the pharmacokinetics and pharmacodynamics of alisertib in pediatric
patients and to relate drug disposition to toxicity.

SECONDARY OBJECTIVES

- To estimate the duration of objective response and PFS in patients with
recurrent/progressive AT/RT and MRT (Strata A1 and A2).

- To estimate PFS and OS distributions in patients with newly diagnosed AT/RT (Strata B1,
B2, B3, C1 and C2).

- To describe toxicities experienced by patients treated on this trial, specifically any
toxicities of alisertib when administered as a single agent or in combination with other
therapy over multiple courses and toxicities related to proton or photon radiation
therapy.

- To describe the patterns of local and distant failure in newly diagnosed patients
(Strata B1, B2, B3, C1 and C2). Local control relative to primary-site radiation
therapy, with criteria for infield, marginal, or distant failure will also be reported
descriptively.

We propose a study with 3 primary treatment strata according to participant's previous
treatment, age and presence of extra-CNS disease, with substrata for presence of focal or
metastatic disease:

- STRATUM A - RECURRENT OR PROGRESSIVE DISEASE: Patients < 22 years of age at diagnosis
with recurrent or progressive MRT (either CNS and/or extra-CNS) and measurable disease
as defined in the protocol.

- Stratum A1: patients with AT/RT (CNS MRT).

- Stratum A2: patients with extra-CNS MRT (patients with concurrent progression of
AT/RT and MRT are eligible for therapy, but their data will be analyzed
separately).

- Stratum A3: patients with synchronous AT/RT and extra-CNS MRT

- STRATUM B - NEWLY DIAGNOSED DISEASE IN YOUNG CHILDREN < 36 MONTHS: Patients < 36 months
of age at diagnosis of CNS-AT/RT, no prior therapy:

- Stratum B1: Patients with no metastatic disease (M0).

- Stratum B2: Patients with metastatic disease (M+) regardless of degree of
resection.

- Stratum B3: Patients for whom CSF by lumbar puncture was not obtained for clinical
reasons and have no other evidence of metastatic disease (MX).

- STRATUM C - NEWLY DIAGNOSED DISEASE IN CHILDREN > 3 YEARS: Patients > 3 years (36
months) of age at diagnosis of AT/RT, no prior therapy:

- Stratum C1: Patients with gross total (GTR) or near total resection (NTR) defined
as <1.5 cm2 of residual tumor, and no metastatic disease.

- Stratum C2: Patients with metastatic disease (M+) and/or bulky residual tumor >1.5
cm^2.

STRATUM D - SYNCHRONOUS EXTRANEURAL AT/RT and EXTRA-CNS MRT: Treatment will be based on the
extent of both CNS and extra-CNS disease. CNS-directed therapy will be given according to
Strata B1, B2, C1 or C2 according to age and metastatic status. In addition, patients may
receive irradiation according to best clinical management for local control of extra-CNS
disease.

- Stratum D1: Patients < 36 months at time of diagnosis with synchronous AT/RT and
extra-CNS MRT and no metastatic CNS disease (M0).

- Stratum D2: Patients < 36 months at time of diagnosis with synchronous AT/RT and extra-
CNS MRT and metastatic CNS disease (M+).

- Stratum D3: Patients < 36 months at time of diagnosis with synchronous AT/RT and
extra-CNS MRT for whom CSF by lumbar puncture was not obtained for clinical reasons and
without other evidence of metastatic disease (MX)

- Stratum D4: Patients ≥ 36 months at time of diagnosis with synchronous extra-CNS MRT
with or without metastatic CNS disease regardless of the degree of tumor resection.

Biological parents of participants with ATRT/MRT may consent to and provide a genomic blood
specimen for DNA extraction and analysis.

OVERVIEW OF TREATMENT PLAN: Patients with recurrent disease (Stratum A) will receive
alisertib as a single agent days 1-7 out of 21 days. Newly diagnosed patients (Strata B, C
and D) will receive alisertib in sequence with chemo and radiotherapy. Patients on sub-strata
B1 and D1 will receive focal RT once they are >12 months of age. Patients on sub-strata B2
and D2, with disseminated disease will not receive CNS radiation therapy (RT). Patients on
sub-strata C1/C2/D4 will receive risk-stratified craniospinal irradiation (CSI) and boost to
primary tumor site followed by adjuvant chemotherapy. Patients on sub-strata B3 and D3 will
receive therapy similar to sub-strata B2 and D2 and will be considered for local radiotherapy
depending on their age, response to therapy, and subsequent metastatic staging. Those
patients with concurrent CNS and extra-CNS MRT may undergo irradiation of the extra-CNS MRT
according to best clinical management in addition to CNS directed therapy. Alisertib will be
administered only to eligible patients under the supervision of the investigator or
identified sub-investigator(s).

INCLUSION CRITERIA for Patients on All Strata EXCEPT Stratum P

- Patients must be < 22 years of age at time of diagnosis (e.g., eligible until 22nd
birthday).

- Histologic diagnosis of AT/RT or MRT as documented by the institutional pathologist
with loss of INI1 or BRG1 expression in tumor cells confirmed by immunohistochemistry,
or by molecular confirmation of tumor-specific biallelic SMARCB1/SMARCA4 loss/mutation
if INI1/BRG1 immunohistochemistry is not available. For Stratum A participants,
histologic confirmation of the diagnosis of AT/RT or MRT may be from the original
diagnosis or at the time of recurrence/progression.

- Patients must have adequate organ function (bone marrow, renal, liver), as defined in
the protocol.

- Female patients who are at least 10-years-old or are post-menarchal must have a
negative serum or urine pregnancy test prior to enrollment.

- Patients of childbearing or child fathering potential must be willing to use a
medically acceptable form of birth control, which includes abstinence during study
treatment and 12 months after the last dose of alisertib.

Inclusion Criteria for Stratum A Participants:

- Patients with recurrent or progressive AT/RT/MRT (either CNS and/or extra-CNS) with
radiographically measurable disease as defined by at least 1 lesion that can be
measured in 2 dimensions or with tumor cells present in the CSF taken within 2 weeks
prior to enrollment.

- Performance status defined by Karnofsky or Lansky > 60 (except for patients with
posterior fossa syndrome). Use Karnofsky for patients > 16 years and Lansky for
patients < 16 years. Note: Patients who are unable to walk because of paralysis, but
who are up in a wheelchair, will be considered to be ambulatory for the purpose of
assessing the performance score.

- Patient has fully recovered from the acute toxic effects of chemotherapy,
immunotherapy, or radiation therapy prior to entering this study:

- Myelosuppressive chemotherapy: Patient has not received myelosuppressive
chemotherapy within 3 weeks of enrollment onto this study (4 and 6 weeks if prior
temozolomide and nitrosourea, respectively).

- Hematopoietic growth factors: At least 7 days must have elapsed since the
completion of therapy with a growth factor. At least 14 days must have elapsed
after receiving pegfilgrastim.

- Biologic (anti-neoplastic agent): At least 7 days must have elapsed since
completion of therapy with a biologic agent. For agents that have known adverse
events occurring beyond 7 days after administration, this period prior to
enrollment must be extended beyond the time during which adverse events are known
to occur.

- Monoclonal antibodies: At least 3 half-lives must have elapsed since prior
therapy that included a monoclonal antibody (see Appendix I).

- Radiation therapy: at least 3 months must have elapsed since any irradiation
unless measurable disease progression occurs at a site separate from the
irradiated area and the patient has recovered from toxicities associated with
radiation therapy.

- Patients with progressive synchronous/metachronous AT/RT and MRT will be eligible for
stratum A3.

- Patients may not have previously received alisertib.

- Live expectancy >8 weeks.

- Stable neurologic deficits on a stable dose of corticosteroids (if applicable) for at
least 1 week before study enrollment.

Inclusion Criteria for Strata B or C Participants:

- Patients with newly diagnosed AT/RT.

- Performance status defined by Karnofsky or Lansky > 30 (except for patients with
posterior fossa syndrome). Other requirements of performance evaluation are the same
as for Stratum A participants.

- No previous anticancer therapy (radiation therapy or chemotherapy) other than the use
of corticosteroids.

- Patients must begin treatment as outlined in the protocol within 42 days of definitive
surgery (day of surgery is day 0; definitive surgery includes last surgery to resect
residual tumor).

Inclusion Criteria for Stratum D Participants:

- Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT.

- Performance status defined by Karnofsky or Lansky > 30 (except for patients with
posterior fossa syndrome). Other requirements of performance evaluation are the same
as for Stratum A participants.

- No previous anticancer therapy (radiation therapy or chemotherapy) other than the use
of corticosteroids.

- Patients must begin treatment within 42 days of definitive surgery (day of surgery is
day 0; definitive surgery includes repeat surgeries to resect residual tumor).

Inclusion Criteria for Stratum P Participants:

- Biological parent of patient enrolling on the protocol (SJATRT) will be assigned to
Stratum P.

EXCLUSION CRITERIA for All Strata Except Stratum P:

- Clinically significant medical disorders that could compromise the ability to tolerate
protocol therapy or that would interfere with the study procedures or results history.

- Presence of an active, uncontrolled infection.

- Known history of uncontrolled sleep apnea syndrome or other conditions that could
result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary
disease or a requirement for supplemental oxygen.

- Requirement for constant administration of proton-pump inhibitor, H2 antagonist, or
pancreatic enzymes. Intermittent uses of antacids or H2 antagonists are allowed while
patients are on dexamethasone as described in the protocol.

- Inability to comply with the safety monitoring requirements of the study, as judged by
the investigator.

- Female participants of childbearing potential cannot be pregnant or breast-feeding.

- Patients who are receiving other investigational drugs 14 or fewer days before
enrollment.

- Treatment with clinically significant enzyme inducers, such as the enzyme-inducing
antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or with rifampin,
rifabutin, rifapentine, or St. John's wort within 7 days prior to initiation of
alisertib.

- Known gastrointestinal disease or procedures that could interfere with the oral
absorption or tolerance of alisertib. Examples include, but are not limited to partial
gastrectomy, history of small intestine surgery, and celiac disease.

- Myocardial infarction within 6 months prior to enrollment or New York Heart
Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
conduction system abnormalities. If for some reason an electrocardiogram is obtained
before study enrollment, any abnormalities detected should be documented as clinically
irrelevant.

- Other severe acute or chronic medical or psychiatric condition, including uncontrolled
diabetes, malabsorption, resection of the pancreas or upper small-bowel, or
requirement for pancreatic enzymes, any condition that would modify the absorption of
oral medications in the small bowel or any laboratory abnormality that may increase
the risk associated with study participation or investigational product administration
or that may interfere with the interpretation of study results and, in the judgment of
the investigator, would make the patient inappropriate for enrollment in this study.
We found this trial at
11
sites
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Lindsay B. Kilburn, MD
Phone: 202-476-2800
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Ashley Margol, MD
Phone: 323-361-4110
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Santhosh Upadhyaya, MD
Phone: 901-595-2544
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1405 Clifton Road NE
Atlanta, Georgia 30322
404-785-6000
Principal Investigator: Dolly Aguilera, MD
Phone: 404-785-1441
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Kathleen Dorris, MD
Phone: 720-777-6672
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Patricia Baxter, MD
Phone: 832-824-1000
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Principal Investigator: Anne Bendel, MD
Phone: 651-220-6732
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Amy A. Smith, MD
Phone: 321-841-7246
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Sonia Partap, MD
Phone: 650-723-0993
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
San Diego, California 92123
Principal Investigator: John Crawford, MD, MS
Phone: 858-576-1700
?
mi
from
San Diego, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Sarah Leary, MD
Phone: 866-987-2000
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials